about
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with shorter disease durationThe role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders.Comparison and Interpretability of the available Urticaria Activity Scores.Clinical Measures of Chronic Urticaria.Cholinergic urticaria patients of different age groups have distinct features.Prevalence of nonspecific cutaneous vascular lesions and association with antiphospholipid antibodies in patients with systemic lupus erythematosus.C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria.Polidocanol inhibits cowhage - but not histamine-induced itch in humans.Substance P is upregulated in the serum of patients with chronic spontaneous urticaria.Serum neuron specific enolase - a novel indicator for neuropsychiatric systemic lupus erythematosus?The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels.In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional.The Urticaria Activity Score-Validity, Reliability, and Responsiveness.Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.Responsiveness and minimal important difference of the urticaria control test.Patients with chronic cold urticaria may benefit from doxycycline therapy.Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge.Somatic-type delusional disorder: a case report and commentsCombined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitisH1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticariaThe response to treatment in chronic spontaneous urticaria depends on how it is measuredDiagnosis and treatment of chronic inducible urticariaDisease activity and stress are linked in a subpopulation of chronic spontaneous urticaria patientsCharacterization of cowhage-induced pruritus in inflamed and non-inflamed skinComparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhageNew treatments for chronic urticariaAntinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSUEosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment
P50
Q35185887-35B42D26-1098-4C47-9DC2-98F27096656DQ35226381-4BFEAC81-A05B-4F3D-AA27-E83CE4879E07Q38228838-096B57AC-E1A7-4792-B7E3-71A128857242Q38620912-AEE93417-16DA-408C-8397-B12261D09724Q39019897-181A4F12-B401-4731-A2DB-3B838394F053Q40057336-6F983ECB-9CF3-41D5-A58E-927C629028F0Q45263272-A653E8D4-5703-4542-8E43-A8137920FA08Q47410715-9277764D-EF96-45EA-B510-7238A5F87DCAQ47807299-0F28F0F3-9203-451B-A917-F5A4C0080BCCQ47873771-8A07A495-C192-4B08-99D0-93FA79B3B7C5Q48079168-E4282062-81F6-40D6-9E12-6DE0288A8E06Q48104058-9F279F35-E836-44FE-906A-B3E7EBD20FBAQ48256184-D03D1380-8032-4300-B6D1-29CA859E1826Q49034395-BE6789C6-6968-4B3D-BBDD-91E94DC6166CQ50058577-9BE0CA2C-D04B-4CFE-9C0F-F14AD169BA61Q50224002-A68D7C24-330A-4E36-A7F1-F8B0BD35F32BQ50275633-A7CE323C-E49D-4530-ACDB-502397486A46Q51067258-AA6BBFE4-82D0-4115-969F-6F7205954DBAQ52837975-CBCE95A4-9DE4-41DA-9E70-72D1891A761AQ52850640-F6A09F89-2786-4B59-A2E6-20020DC4DA7BQ52877128-954B1785-1F02-4463-B59B-AE96C05F15E2Q52879396-31C3FF48-430A-411E-8401-C01A1E335F8EQ52881764-085C87B1-6D0D-47AC-A065-5E0CD4A4DE1CQ82214938-2A53CBC7-A9DB-4E4C-9FED-DBA292FE68A6Q83680143-01212583-5F20-460B-942C-3976CC496677Q91306067-4C20A2C2-5E75-44F0-B59E-D28607C52321Q91399811-9644E91D-0E9F-490B-8E11-5484BF67B042Q92130175-EF2C2819-8027-4DFD-B92C-9D33C3CBB628Q92491335-83D6AAB6-F255-4202-A638-570387FF12F5Q92661376-D6384DB2-06CD-47EE-BDCC-0572A3F7ACDEQ92749449-557E7F6E-6261-4CD7-BA53-287C843AA283Q92846417-03D99717-9206-4438-A71E-E92A2ADABBDEQ93012317-43BAF8F4-7B5C-41D0-8EB5-3F27CB0B8DC4Q93029359-1662CCFD-17F9-4084-BCC4-5B1A38BCA947
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Tomasz Hawro
@en
Tomasz Hawro
@nl
type
label
Tomasz Hawro
@en
Tomasz Hawro
@nl
prefLabel
Tomasz Hawro
@en
Tomasz Hawro
@nl
P31
P496
0000-0001-9990-1332